Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: J Autoimmun. 2019 May 10;102:150–158. doi: 10.1016/j.jaut.2019.05.002

Fig. 1.

Fig. 1

(A) Representative dot plots of transitional B cells and their subsets in one HD and one SLE patient. (B) Frequency of transitional B cells (top left panel) and their subsets (bottom panel) (% of CD19+) in HDs compared to SLE patients. Correlation between transitional B cells (% of CD19+) and disease activity assessed by the SLEDAI-2K score (top right panel). (C) MFI of CD19 in transitional B cells subsets from HDs and SLE patients. (D) Frequency of CD86+CD69+ transitional B cells from HDs or SLE patients after no stimulation (NS) or in vitro stimulation with CD40L (CD40 ligand), R848 (TLR7 agonist) or CpG (TLR9 agonist) for 2 days. HDs: healthy donors; MFI: mean of fluorescence intensity; SLE: Systemic lupus erythematosus.